Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model

Molecular Medicine

Volumn 8, Issue 8, 2002, Pages 487-494

  Kawakami, Koji ^a   Husain, Syed R ^a   Kawakami, Mariko ^a   Puri, Raj K ^a  

^a Center for Biologics Evaluation/Res   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; INTERLEUKIN 13 CYTOTOXIN; INTERLEUKIN 13 PE38QQR; INTERLEUKIN 13 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; GROWTH INHIBITION; HEAD CANCER; HISTOPATHOLOGY; INFUSION PUMP; KIDNEY NECROSIS; LIVER NECROSIS; MAXIMUM TOLERATED DOSE; MOUSE; NECK CANCER; NONHUMAN; NUDE MOUSE; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SPLEEN DISEASE; TOXICITY; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 0036705806     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402028     Document Type: Article

References (42)

1. Drixler TA, Borel Rinkes IHM, Ritchie ED, van Vroonhoven TJMV, Gebbink MFBG, Voest EE. (2000) Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 60: 1761-1765.
2. Cohen-Jonathan E, Muschel RJ, McKenna WG, et al. (2000) Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat. Res. 154: 125-132.
3. Tejeda M, Gaal D, Schwab RE, Pap A, Szuts T, Keri GY. (2000) Influence of various administration routes on the antitumor efficacy of TT-232, a novel somatostatin analog. Anticancer Res. 20: 1023-1028.
4. Thomas-Vaslin V, Bellier B, Cohen JL, et al. (2000) Prolonged allograft survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene. Transplantation 69: 2154-2161.
5. Minty A, Chalon P, Derocq JM, et al. (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature (Lond) 36: 248-251.
6. Kapp U, Yeh WC, Patterson B, et al. (1999) Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med. 189: 1939-1946.
7. Obiri NI, Debinski W, Leonard WJ, Puri RK. (1995) Receptor for interleukin 13: Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J. Biol. Chem. 270: 8797-8804.
8. Puri RK, Leland P, Obiri NI, et al. (1996) Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87: 4333-4339.
9. Husain SR, Obiri NI, Gill P, et al. (1997) Receptor for interleukin-13 on AIDS-associated Kaposi's sarcoma cells served as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res. 3: 151-156.
10. Husain SR, Puri RK. (2000) Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 95: 3506-3513.
11. Joshi BH, Plautz GE, Puri RK. (2000) IL-13 receptor α chain: a novel tumor associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60: 1168-1172.
12. Kawakami M, Leland P, Kawakami K, Puri RK. (2001) Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol. Res. 12: 459-467.
13. Maini A, Hillman G, Haas GP, et al. (1997) Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J. Urol. 158: 948-953.
14. Murata T, Obiri NI, Debinski W, Puri RK. (1997) Human ovarian carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J. Cancer 70: 230-240.
15. Kawakami M, Kawakami K, Puri RK. (2002) Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol. Immunother. 50: 691-700.
16. Kawakami K, Kawakami M, Joshi BH, Puri RK. (2001) Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 61: 6194-6200.
17. Joshi BH, Kawakami K, Leland P, Puri RK. (2002) Heterogeneity of interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to a chimeric fusion protein comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin. Cancer Res. 8: 1948-1956.
18. Murata T, Noguchi PD, Puri RK. (1996) IL-13 induces phosphorylation and activation of JAK2 Janus Kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J. Immunol. 156: 2972-2978.
19. Obiri NI, Leland P, Murata T, Debinski W, Puri RK. (1997) The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J. Immunol. 158: 756-764.
20. Murata T, Obiri NI, Puri RK. (1998) Structure of and signal transduction through interleukin-4 and interleukin-13 receptors. Int. J. Mol. Med. 1: 551-557.
21. Murata T, Husain SR, Mohri H, Puri RK. (1998) Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int. Immunol. 10: 1103-1110.
22. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola N, Willson TA. (1996) Cloning and characterization of a binding subunit of the interleukin-13 receptor that is a component of the interleukin-4 receptor. Proc. Natl. Acad. Sci. U.S.A. 3: 497-501.
23. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ. (1996) cDNA cloning and characterization of the human interleukin 13 receptor α chain. J. Biol. Chem. 271: 29265-29270.
24. Miloux B, Laurent P, Bonnin O, et al. (1997) Cloning of the human IL-13Rα1 chain and reconstitution with the IL-4Rα of a functional IL-4/IL-13 receptor complex. FEBS Lett. 401: 163-166.
25. c chain of the IL-2 receptor. J. Biol. Chem. 272: 20251-20258.
26. Caput D, Laurent P, Kaghad M, et al. (1996) Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J. Biol. Chem. 271: 16921-16926.
27. Donaldson DD, Whitters MJ, Fitz LJ, et al. (1998) The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J. Immunol. 161: 2317-2324.
28. Kawakami K, Taguchi J, Murata T, Puri RK. (2001) The Interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for IL-13 induced signal transduction through the STAT6 pathway. Blood 276: 2673-2679.
29. Kawakami K, Takeshita F, Puri RK. (2001) Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin-13 binding component IL-13 receptor α2 chain. J. Biol. Chem. 276: 25114-25120.
30. Debinski W, Obiri NI, Pastan I, Puri RK. (1995) A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270: 16775-16780.
31. Kawakami K, Joshi BH, Puri RK. (2000) Sensitization of cancer cells to interleukin 13-Pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor α chain. Hum. Gene Ther. 11: 1829-1835.
32. Kawakami K, Husain SR, Bright RK, Puri RK. (2001) Gene transfer of interleukin 13 receptor α2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 8: 861-868.
33. Husain SR, Joshi BH, Puri RK. (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92: 168-175.
34. Frankel, AE, Kreitman RJ, Sausville EA. (2000) Targeted toxins. Clin. Cancer Res. 6: 326-334.
35. Kreitman RJ, Wilson WH, White JD, et al. (2000) Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18: 1622-1636.
36. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJP, Pastan I. (2000) Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin. Cancer Res. 6: 1476-1487.
37. Cardinali M, Pietraszkiewicz H, Ensley JF, Robbins KC. (1995) Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int. J. Cancer 61: 98-103.
38. Kawakami K, Leland P, Puri RK. (2000) Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res. 60: 2981-2987.
39. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. U.S.A. 97: 8548-8553.
40. Onda M, Olafsen T, Tsutsumi Y, Bruland OS, Pastan I. (2001) Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A. J. Immonother. 24: 144-150.
41. Durect Corporation. (2000) Technical information manual, ALZET osmotic pumps. pp 1, Palo Alto.
42. Prados M, Lang F, Strauss L, et al. (2001) Pre- and post-resection interstitial infusions of IL13-PE38QQR cytotoxin: phase I study in recurrent respectable malignant glioma. World Federation of Neuro-Oncology First Quadrennial Meeting, Washington D.C.